|Day Low/High||63.57 / 64.44|
|52 Wk Low/High||54.63 / 66.80|
Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.
Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.
The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, will be presented at the 53 rd...
Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.
Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck's diabetes pipeline and portfolio - including Phase 3 data for investigational ertugliflozin,...
Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.
Stocks hold modest losses on Thursday as a selloff in Snap pulls the rest of the tech sector lower, while Macy's leads other retailers lower.
The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.
Stock losses accelerate on Thursday as a disappointing quarter from Macy's spooks the rest of the retail sector.
Stock futures move lower on Thursday after Snap disappoints in its first earnings report since going public.
Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?
Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday
The price momentum and money flow indicators of the drug maker are in positive alignment.
Selling premium on big names vs. buying premium has been the superior strategy this earnings season.
Doug Kass shares his thoughts on Facebook, Allergan and Apple.